📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 18:19
4 analysed today
FollowTelegram
4
Today
149,943
All-time analysed
42,986
Positive
6,669
Negative
91,580
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
₹54 Open Offer for 26% Stake in Colinz Laboratories: Reminder Advertisement Issued
The Dugar family (Acquirers) has issued a reminder advertisement for their open offer to acquire 6,54,966 shares, representing a 26% stake in Colinz Laboratories. The offer price is fixed at ₹54 per share, totaling ₹3.54 Cr, which is approximately 17.7% of the company's current market capitalization of ₹20 Cr. Notably, the offer price is at a significant discount of approximately 32% to the current market price of ₹79.7. This mandatory offer follows a shift in the promoter holding structure, which recently decreased from 66% to 50.6%.
Confidence: HIGH
What changedThe acquirers have issued a formal reminder advertisement as part of the regulatory timeline for their mandatory open offer to public shareholders.
Why it mattersThis represents a potential change in control or consolidation of ownership in a micro-cap pharmaceutical company with a market cap of only ₹20 Cr.
Offer Price: ₹54Stake Offered: 26%Total Offer Value: ₹3.54 CrOffer Value vs Market Cap: ~17.7%Current Market Price: ₹79.7
📅 Short termThe stock may see limited impact from the offer itself since the offer price is well below the market price, but volatility may persist due to the low market cap.
📈 Long termThe long-term impact depends on the new acquirers' ability to scale the business, which currently has a small TTM revenue of ₹6 Cr and OPM of 6.5%.
⚠ Risk flags
- Offer price is at a steep discount to market price
- Micro-cap stock with low liquidity
- Potential management transition risks
Key Highlights
Open offer to acquire up to 6,54,966 fully paid-up equity shares, representing 26% of voting capital.
Offer price set at ₹54 per share, a ~32% discount to the current market price of ₹79.7.
Total offer consideration aggregates to ₹3,53,68,164 (₹3.54 Cr).
Reminder advertisement published on August 12, 2026, in Financial Express, Jansatta, and Pratahkal.
Acquirers include Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, with Padam Dugar as PAC.
👀 What to Watch
Monitor the completion of the open offer and any subsequent changes in management or business strategy. Given the offer price is significantly below the current market price, retail shareholders are unlikely to find the offer attractive for tendering shares.
₹54 Open Offer for 26% Stake in Colinz Laboratories by Dugar Family
Annjana Dugar, Likhitta Dugar, and Antariksh Dugar (the Acquirers) have announced an open offer to acquire up to 6,54,966 shares of Colinz Laboratories, representing 26% of the voting share capital. The offer price is set at ₹54 per share, which is a significant discount to the current market price of ₹81.7. The total offer size is valued at approximately ₹3.54 crore. This follows a recent decline in promoter holding from 66.0% in March 2026 to 50.6% in June 2026.
Confidence: HIGH
What changedThe company has moved to the next regulatory stage of a mandatory open offer with the publication of the offer opening public announcement and corrigendum.
Why it mattersThis transaction indicates a potential consolidation of control by the Dugar family. For a micro-cap company with a ₹21 Cr market cap, a 26% stake acquisition is highly material and could lead to changes in management or strategic direction.
Offer Price: ₹54Current Market Price: ₹81.7Offer Size (Shares): 6,54,966Total Offer Value: ₹3.54 CrOffer Value vs Market Cap: ~16.8%Stake Offered: 26%
📅 Short termThe stock may experience volatility as the market reacts to the low offer price. The gap between the market price and the offer price suggests limited immediate incentive for retail investors to tender shares.
📈 Long termThe long-term impact depends on the final shareholding structure post-offer and whether the new controlling group implements operational changes to improve the current 6.5% operating margins.
⚠ Risk flags
- Offer price is at a significant discount to market price
- Low liquidity in micro-cap stock (₹21 Cr M-Cap)
- Potential for low acceptance ratio
Key Highlights
Open offer to acquire 6,54,966 fully paid-up equity shares representing 26% of voting capital
Offer price fixed at ₹54 per share, totaling an aggregate value of ₹3,53,68,164
Acquirers include Annjana Dugar, Likhitta Dugar, and Antariksh Dugar with Padam Dugar as PAC
Offer price represents a ~34% discount to the current market price of ₹81.7
Public announcement published on August 06, 2026, in Financial Express and other newspapers
👀 What to Watch
Investors should monitor the official offer opening and closing dates. Given the offer price (₹54) is substantially lower than the current market price (₹81.7), the acceptance ratio from public shareholders may be low unless the market price corrects.
₹54 Open Offer for 26% Stake in Colinz Laboratories by Dugar Family
The Dugar family (Acquirers) has issued a formal Letter of Offer to acquire up to 6,54,966 shares, representing 26% of the voting capital of Colinz Laboratories. The offer price is set at ₹54 per share, which is a significant 32.5% discount to the current market price of ₹80. The total consideration for the offer amounts to ₹3.54 crore, representing approximately 17.7% of the company's current market capitalization of ₹20 crore. This follows a recent drop in promoter holding from 66.0% to 50.6% in the June 2026 quarter.
Confidence: HIGH
What changedA formal Letter of Offer has been filed by new acquirers (the Dugar family) to take a substantial stake and control of the company.
Why it mattersA change in control in a micro-cap company (₹20 Cr M-Cap) with low margins (6.5%) could lead to a shift in business strategy or capital infusion, which is critical for a firm with only ₹6 Cr in annual revenue.
Offer Price: ₹54Current Market Price: ₹80.0Offer Size (Shares): 6,54,966Total Offer Value: ₹3.54 CrOffer Value vs Market Cap: 17.7%
📅 Short termThe stock may experience volatility as the market digests the entry of new acquirers and the low offer price relative to the current market price.
📈 Long termThe long-term outlook depends entirely on the new management's ability to scale the pharmaceutical business, which currently has a low ROCE of 7.2%.
⚠ Risk flags
- Offer price is at a steep discount to market price
- Change in management/control risk
- Low liquidity in micro-cap stocks
Key Highlights
Open offer to acquire 6,54,966 fully paid-up equity shares at ₹54 each
Offer represents 26% of the total voting share capital of the company
Total offer consideration aggregates to ₹3,53,68,164
Offer price of ₹54 is at a 32.5% discount to the current market price of ₹80
Promoter holding decreased from 66.0% in March 2026 to 50.6% in June 2026
👀 What to Watch
Investors should monitor the tendering period dates and the post-offer shareholding structure. Given the market price is significantly higher than the offer price, the offer is currently unattractive for tendering, but the change in control is a major event for this micro-cap company.
40th AGM Scheduled and CEO Tenure Extended for 1 Year at Colinz Laboratories
Colinz Laboratories held a board meeting on July 30, 2026, to approve the un-audited financial results for the quarter ended June 30, 2026. The board confirmed the 40th Annual General Meeting (AGM) for September 22, 2026, and set the share transfer book closure from September 15 to September 22, 2026. Key leadership decisions include the re-appointment of Mr. N. K. Menon as CEO for a one-year term and the appointment of Mrs. Vijaya Mani as a Promoter Director. New internal and secretarial auditors were also appointed for the 2026-27 financial year.
Confidence: HIGH
What changedThe company has formalized its AGM timeline and extended the tenure of its current CEO by one year while adding a new promoter director to the board.
Why it mattersFor a micro-cap company with a Rs 21 Cr market cap, leadership continuity and regulatory compliance are essential for maintaining investor confidence and operational stability.
CEO Tenure Extension: 1 YearAGM Date: September 22, 2026Cut-off Date: September 15, 2026Market Cap: Rs 21 CrTTM Revenue: Rs 6 Cr
📅 Short termThe stock may remain neutral as the announcement is primarily administrative; the actual Q1 financial performance figures will be the primary driver.
📈 Long termLimited structural change; the one-year extension for the CEO suggests a short-term leadership horizon which may need monitoring for succession planning.
⚠ Risk flags
- Micro-cap liquidity risk
- Short-term CEO tenure extension (1 year)
Key Highlights
Re-appointment of Mr. N. K. Menon as Whole-time Director and CEO for a 1-year term effective October 1, 2026
40th Annual General Meeting (AGM) to be held on September 22, 2026, via video conferencing
Book closure for the AGM set from September 15, 2026, to September 22, 2026
Cut-off date for e-voting eligibility fixed as September 15, 2026
Appointment of CA Ajay Ramsevak Sharma as Internal Auditor for FY 2026-27
👀 What to Watch
Investors should review the detailed Q1 FY27 financial results once the full tables are released to compare against the TTM revenue of Rs 6 Cr and check for margin improvements.
Colinz Laboratories Approves Q1 Results; Re-appoints CEO for 1-Year Term
Colinz Laboratories held its board meeting on July 30, 2026, approving the un-audited financial results for the quarter ended June 30, 2026. The board re-appointed Mr. N. K. Menon as Whole-time Director and CEO for a further one-year term effective October 1, 2026. Additionally, the company scheduled its 40th Annual General Meeting (AGM) for September 22, 2026, and appointed new internal and secretarial auditors for FY27. Mrs. Vijaya Mani was also appointed as a Promoter and Non-Executive Director.
Confidence: HIGH
What changedThe company has extended the CEO's tenure by one year and formalized the schedule for its upcoming AGM and auditor appointments.
Why it mattersFor a micro-cap company with a Rs 21 Cr market cap, leadership continuity and timely financial reporting are essential for maintaining investor confidence and regulatory compliance.
CEO Tenure Extension: 1 yearAGM Date: September 22, 2026Book Closure Period: Sept 15 to Sept 22, 2026TTM Revenue: Rs 6 CrMarket Capitalization: Rs 21 Cr
📅 Short termThe stock may remain neutral as the announcement primarily covers administrative approvals and routine management extensions.
📈 Long termLimited structural impact; the one-year extension for the CEO suggests a short-term leadership horizon which may need monitoring for succession planning.
⚠ Risk flags
- Promoter holding decreased from 66.0% in March 2026 to 50.6% in June 2026
- Micro-cap liquidity risks
- Short 1-year extension for CEO
Key Highlights
Approved un-audited financial results for the quarter ended June 30, 2026
Re-appointed Mr. N. K. Menon as CEO for a 1-year term from October 1, 2026, to September 30, 2027
Scheduled the 40th Annual General Meeting for September 22, 2026, via video conferencing
Fixed September 15, 2026, as the cut-off date for determining shareholder eligibility for e-voting
Appointed CA Ajay Ramsevak Sharma as Internal Auditor for the financial year 2026-27
👀 What to Watch
Investors should review the detailed Q1 FY27 financial statements once released to assess if the company is maintaining its TTM revenue of Rs 6 Cr and OPM of 6.5%.
